Intended for healthcare professionals

  1. Education
  2. Analgesia for non...
  3. Analgesia for non-specific low back pain
CCBYNC Open access
Practice Clinical Update

Analgesia for non-specific low back pain

BMJ 2024; 385 doi: https://doi.org/10.1136/bmj-2024-080064 (Published 27 June 2024) Cite this as: BMJ 2024;385:e080064
  1. Caitlin M P Jones, postdoctoral research associate1,
  2. Martin Underwood, professor of primary care research2 3,
  3. Roger Chou, professor4,
  4. Mark Schoene, patient representative5,
  5. Saniya Sabzwari, professor6,
  6. Jarrod Cavanagh, patient representative7,
  7. Chung-Wei Christine Lin, professor1
  1. 1Institute for Musculoskeletal Health, University of Sydney and Sydney Local Health District, Camperdown NSW, Australia
  2. 2Warwick Clinical Trials Unit, Warwick Medical School, Coventry, UK
  3. 3University Hospitals of Coventry and Warwickshire, Coventry, UK
  4. 4Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, USA
  5. 5Cochrane Collaboration, Back and Neck Review Group, Newbury MA, USA
  6. 6Department of Family Medicine, Aga Khan University, Karachi, Pakistan
  7. 7Brisbane, Queensland, Australia
  1. Correspondence to: C M P Jones caitlin.jones{at}sydney.edu.au

What you need to know

  • Analgesics have limited effect on low back pain and some, such as opioids and benzodiazepines, have substantial risks

  • Oral and, less certainly, topical non-steroidal anti-inflammatory drugs have small benefits that may not be outweighed by risks (particularly gastrointestinal) for short term use for low back pain

  • Acute low back pain typically improves within a few weeks without treatment; for chronic low back pain, the focus of management should be on non-pharmacological treatments to improve function and address the broader determinates of pain

Low back pain is the world’s leading cause of disability.1 At any time, half a billion (9%) adults are affected.1 Many are prescribed, or use, analgesics for pain relief.2 In this article, we review what is known about common analgesics for treating non-specific low back pain (defined as pain without an identifiable structural or disease cause). We focus on adults aged 18-60 years. A previous BMJ education paper describes the management of low back pain in people aged 60 and over, in whom the likelihood of there being a specific cause is greater and the risk-benefit balance of analgesics differs.3 The treatment of radicular low back pain (such as sciatica) has been detailed elsewhere4 and is not addressed here.

What is low back pain?

Low back pain (synonymous with “primary” low back pain) is pain felt between the lower ribs and the buttocks.5 This differs from radicular low back pain, which is when a spinal nerve root is affected, resulting in pain that extends down the legs.6 Approximately 90% of cases are non-specific, meaning a specific cause has not been identified. The causes of the remaining 10%, affecting around <1 in 100 in primary care7 and about 5 in 100 in emergency departments,8 include fractures, infections, malignancies, inflammatory disorders such as spondylarthritis, spinal stenosis, or non-spinal problems such as kidney problems or menstrual related pain.9

The prognosis for a new episode of non-specific low back pain is good. Most people recover from acute low back pain within a few weeks irrespective of any treatment.5 Some people, however, develop chronic low back pain (typically defined as symptoms lasting for over three months), either as a fluctuating/recurring or continuous problem.10 Of those who present to primary care with acute low back pain, a quarter will have some ongoing pain or functional impairment at three months (chronic pain), although the estimates from individual studies range widely from 2% to 48%.11

Who is affected?

Low back pain affects all people of all ages, genders, and ethnic or racial groups, although the point prevalence is slightly higher in women than men (~10% absolute difference consistently across age groups).12 Prevalence peaks in the 40-69 years age group.12 Disability resulting from low back pain is similar in high, middle, and lower income countries113 and in urban and rural areas.12 A 2018 umbrella review identified 54 risk factors associated with low back pain.14 Examples of potentially modifiable ones include current smoking (odds ratio (OR) 1.8 (95% confidence interval 1.3 to 2.7)), sleep problems (OR 3.2 (1.9 to 5.5)), >2 hours daily spent driving (OR 4.9 (1.4 to 16.4)), prolonged standing or walking (OR 2.9 (1.5 to 5.5)), and mental distress (OR 2.2 (1.3 to 3.7)).14

How is low back pain managed?

Most international guidelines advise non-drug treatment and limited, careful use of some analgesic treatments, including those endorsed by the World Health Organisation, National Institute for Health and Care Excellence (NICE), and the American College of Physicians.15161718 People with non-specific low back pain should be advised to keep active (continue usual physical activities as much as possible), avoid bed rest (as it does not aid recovery),19 and use self management strategies such as heat packs.15 About one in five people with chronic low back pain will experience major life or work limitations and may benefit from further treatment.2021 For people with chronic non-specific low back pain, optimal approaches use physical and psychological therapies that improve function and address psychosocial contributors to low back pain (see infographic and table 1).15

Table 1

Summary of current guideline recommendations for non-specific low back pain

View this table:

Both prescription and over-the-counter analgesics are easily accessible and widely used as an alternative or addition to non-drug treatments. Across primary care services in high income countries Australia,2 Portugal,23 US,24 and Switzerland,25 66-89% of consultations for low back pain result in a prescription for analgesia. There are limited prescribing data from low and middle income countries. Herbal medicines (such as topical cayenne pepper) and homoeopathy are prescribed for low back pain in some settings, but the type of agents used varies between regions and is influenced by cultural practices.2627

Efficacy of analgesia

Most commonly used analgesics used to treat low back pain offer no to small benefit versus placebo, and all have a risk of harm (to varying degrees). In this article, we focus primarily on reporting pain intensity, as this is the outcome most consistently reported in literature and a recommended core outcome across acute and chronic pain studies.28 We also briefly consider other important outcomes such as disability and sleep, which have been shown to correlate with pain. We have included analgesics delivered by any route in this evidence summary.

In table 2, we summarise the efficacy (compared with placebo) of analgesics to reduce low back pain. We summarise data from placebo controlled evidence only because placebo controls in clinical trials are the best method to control for confounding and potential biases.42 Head-to-head studies comparing one analgesic with another are not included in this summary because determining efficacy is the necessary first step before comparative effectiveness can be explored. Where available, we present the between-group difference between medicine and placebo groups using a 0-10 scale. We report the certainty of the evidence as reported by authors of the cited systematic reviews as per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) (box 1).43

Table 2

Summary of evidence from systematic reviews of efficacy of analgesics versus placebo for low back pain

View this table:
Box 1

Certainty of evidence (GRADE)43 and size of treatment effects18

  • High certainty—We are confident that the true effect lies close to that of the estimate

  • Moderate certainty—We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that new research may change the estimate

  • Low certainty—Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

  • Very low certainty—We have very little confidence in the effect estimate: the true effect is uncertain

  • No effect—The point estimate is very close to zero, and the confidence interval is precise around either side of zero

  • Small effect—The point estimate of the between-group difference is less than 1 point out of 10 above that of placebo, with confidence intervals that do not cross zero or cross into what would be considered a moderate effect

  • Moderate effect—The point estimate of the between-group difference is less than 2 points out of 10 above that of placebo, with confidence intervals that do not cross zero or cross into what would be considered a small or large effect

  • Large effect—The point estimate of the between-group difference is ≥2 points out of 10 above that of placebo, with confidence intervals that do not cross zero or cross into what would be considered a small or moderate effect

  • If confidence intervals span multiple effect descriptor categories, we use both descriptors and highlight that the evidence is imprecise or unclear

RETURN TO TEXT

Paracetamol (acetaminophen)

There is moderate to high certainty evidence of no effect over placebo for both acute and chronic low back pain. A systematic review of 13 randomised controlled trials (RCTs) in Australian and Austrian cohorts of patients with low back pain found a mean difference in pain score of −0.5 (95% confidence interval −2.9 to 1.9).29 In trials of patients with low back pain, there was no increased risk of harms. However, in RCTs assessing people with osteoarthritis or low back pain, using paracetamol was more likely to cause abnormal liver function tests (though the clinical importance of the changes remains unknown).29

Observational data and trials in broader populations using paracetamol for any reason (such as other pain, fever) at standard therapeutic doses show a dose-dependent increase in risk of harms (cardiovascular, gastrointestinal, and renal).44 Data informing these risk estimates are potentially confounded by not adjusting for concomitant use of non-steroidal ani-inflammatory drugs (NSAIDs) and by including participants who were unsuitable for NSAIDs (with cardiac, gastrointestinal, and renal risk factors), who are prescribed paracetamol as an alternative. We observe in practice that paracetamol is typically safe when taken as directed in people without contraindications and is generally safer than anti-inflammatories.4546

Non-steroidal anti-inflammatories (NSAIDs)

NSAIDs include ibuprofen, diclofenac, naproxen, and celecoxib. For acute low back pain, there is moderate certainty evidence of small benefit above placebo (mean difference in pain intensity −0.9 (95% CI −1.1 to −0.7) from six RCTs conducted in Norway, Belgium, France, Australia, and Germany)30 and a risk ratio of 2.5 (1.2 to 5.2) of gastrointestinal harms (28/702 participants taking NSAIDs compared with 9/465 in the placebo groups).30 For chronic low back pain, there is low certainty evidence of small average benefits (mean difference −0.7 (−1.1 to −0.3, from six RCTs conducted in Italy, UK, and US).31

The available data from RCTs of chronic low back pain do not report increased risk of harm compared with placebo.31 However, RCTs and observational studies of populations taking NSAIDs for any reason (such as osteoarthritis or rheumatoid arthritis) showed increased NSAID related adverse events (such as gastrointestinal, cardiovascular, and renal) which escalate with increasing doses and long term use.47

Antidepressants

There are no data on antidepressants for treating acute low back pain. For chronic low back pain, there is moderate certainty evidence that serotonin-norepinephrine reuptake inhibitors (such as duloxetine) may have a small effect (mean difference −3.67 (−5.91 to −1.42) from three RCTs conducted in the US and Japan) and low certainty evidence that tricyclic antidepressants are ineffective (mean difference −0.9 (−5.4 to 3.7) from three RCTs conducted in the US and Switzerland).32 Harms when used specifically for low back pain are unclear, although in broader populations (such as mood disorders) antidepressants are associated with nausea, weight gain, sexual dysfunction, and sleep problems.48

Opioids

A 2023 trial conducted in Australia in 347 patients with acute low back pain found strong evidence of no effect of oxycodone (mean difference 0.5 (0.0 to 1.1)), and worse long term outcomes (such as worse pain and a higher risk of opioid misuse) compared with placebo.49 For chronic low back pain, there is moderate certainty evidence that opioids (numerous single or combination opioid formulations including morphine, tramadol alone or with paracetamol, tapentadol, oxycodone, and fentanyl) probably have a small average effect (mean difference −1.0 (−1.3 to −0.7) from 13 RCTs conducted in Germany, US, Canada, and Australia).33 Despite this, opioids are not recommended to treat chronic pain because of risks of harms with long term use, including dependence, misuse, overdose, and tolerance resulting in dose escalations that may further contribute to increased risk of harms.3350

Anticonvulsants

There are no data on efficacy for acute low back pain. However, there is high certainty evidence of no effect above placebo of gabapentin or pregabalin for chronic low back pain (mean difference 0.0 (−0.8 to 0.7) from 14 RCTs conducted in Australia, US, and Ireland).34 The use of anticonvulsants causes increased risk of harms including drowsiness, somnolence, dizziness, and nausea.3451

Benzodiazepines

Small trials conducted in the 1970s to 1990s report some effect on acute or chronic low back pain (effect size and level of certainty not reported).35 Other studies indicate that benzodiazepines do not possess meaningful analgesic properties separate from their sedative properties.52 A 2017 RCT of 114 patients conducted in the US did not find that that adding diazepam to diclofenac in people attending an emergency department improved functional outcomes or pain at one week.53 Benzodiazepines are associated with increased falls, cognitive impairment, and risk of addiction.54

Non-benzodiazepine muscle relaxants

This category of medicine is broad and includes a variety of pharmacologically unrelated medications such as cyclobenzaprine, tolperisone, baclofen, and orphenadrine with similar indications. In both acute and chronic low back pain, there is low and very low certainty evidence that non-benzodiazepine muscle relaxants might offer small benefits (mean difference −0.8 (−1.2 to −0.3) from 14 RCTs from the US, Finland, UK, Turkey, and India) but increase the risk of harms, primarily sedation.36

Oral corticosteroids

Limited evidence suggests they may be not effective for acute or chronic low back pain (mean difference 0.6 (−2.2 to 1.0) from one RCT conducted in the US), and may not cause harm in short courses.37

Cannabinoids

A single RCT of oral cannabidiol in 100 patients conducted in Australia found no effect on low back pain compared with placebo (mean difference −0.3 (−1.3 to 0.6)) and no increase in short term harms in a hyperacute, emergency department setting.55 There are no data for chronic low back pain, and no data on harms associated with long term use in other chronic conditions.38

Oral combination medicines

There is low certainty evidence that combining medicines does not produce superior effect sizes and may increase the risk of harms.56 An example of combination medicines sometimes used to treat low back pain is an opioid plus an NSAID or paracetamol.

Topical preparations

There is some indirect evidence (level of certainty not assessed) that some formulations of NSAIDS and rubefacients may reduce back pain attributed to muscle strains or sprains more than placebo (effect size not reported),39 which may apply to some cases of acute low back pain, with no increased risk of harms.39 There are no data on efficacy for chronic low back pain, but indirect evidence from other chronic pain conditions such as knee osteoarthritis has shown limited effect.39

Homoeopathy

There is no reliable evidence of efficacy of homoeopathy for acute or chronic low back pain.57 While many may consider homoeopathy harmless, some indirect risks may apply, including the risk of harm to patient’s trust and delaying use of treatments that may be more effective such as those recommended in table 1.57

Herbal medicines

Some herbal remedies have reported efficacy compared with placebo (with low to moderate certainty) for both acute and chronic low back pain, such as cayenne or capsaicin plasters, devil’s claw, willow bark, and topical lavender oil.41 However, the size of the effects is unclear due to critical heterogeneity across trials (such as use of a variety of non-standard outcome measures for pain or recovery and widely varying formulations and quality of the herbal products used). Most available trials are limited by authors’ conflicts of interest.41 Harms are uncertain, with suboptimal reporting in trials.41

Dissonance between evidence and practice

Despite limited supportive evidence, analgesics are still commonly used for low back pain.212 In our experience, reasons for this include a real or perceived lack of alternatives, pressure from patients, a strong desire to help, and the lower cost and better accessibility of medicines compared with physical and psychological therapies. We recommend clinicians discuss with patients the evidence and explore more effective alternatives such as those listed in table 1.

If an analgesic is to be recommended for management of low back pain, oral NSAIDs (or topical NSAIDs if there are contraindications to oral formulations) probably have the most favourable benefit-harm balance (see infographic and appendix on bmj.com). There is high to moderate certainty evidence that paracetamol, opioids, antidepressants, and anticonvulsants are not effective. These medicines have associated harms, many of which are serious. Box 2 outlines special considerations when managing patients with low back pain.

Box 2

Special considerations when managing patients with low back pain

  • The evidence presented here should be used to guide clinical practice around starting new medicines for patients who are not already long term users

  • Despite the lack of evidence for efficacy, many people with chronic low back pain are already using long term analgesics

  • Rapid or forced tapering of analgesics with risk of withdrawal (such as opioids, anticonvulsants, and benzodiazepines) can cause serious harm

  • Long term users of medicines should be assessed individually to determine the benefit-harm balance of reducing their use of pain medicines

  • Some patients may require supportive treatments while undergoing tapering, and appropriate treatment for substance use disorders if they are identified58

  • Some of the medicines used for low back pain carry the risk of drug interactions. For example, combining opioids with other sedatives or respiratory depressants, such as benzodiazepines, increases the risk of mortality and serious adverse events59

RETURN TO TEXT

If analgesics are used, international guidelines agree they should be at the lowest effective dose for the shortest duration, and as an adjunct to other non-medicine strategies which address the broader biopsychosocial aspects of pain.161718

How patients were involved in the creation of this article

Two authors of this article are patients. MS had severe chronic disabling back pain and has now recovered. He is a consumer representative at Cochrane Back and Neck since 2000. JC has ongoing chronic disabling back pain that came on after a workplace injury that prevented him working. He has been prescribed various pharmaceutical and non-pharmaceutical strategies. Both authors reviewed multiple drafts of the article. They optimised the use of language throughout, recommended using examples of medicines that patients might be more familiar with than the overarching class, and explained that patient readers may want more explanation about how to interpret effect sizes. They also acknowledged the practical reasons some patients may elect to use medicines that are not supported by empirical evidence.

Other authors CMPJ, MU, and CWCL have all had episodes of acute low back pain.

Education into practice

  • Think about the last time you reviewed a patient who presented with low back pain. What factors led to your decision whether to prescribe an analgesic or not?

  • How might you explain effectiveness and risks of oxycodone to a patient who requests it for low back pain?

Questions for future research

  • How can we reduce prescribing of analgesia when benefits do not outweigh harms?

  • How can we best support people using ineffective drugs for low back pain on a regular basis to stop using these analgesics?

  • How effective are analgesics for low back pain in the immediate term (within 2 hours)?

How this article was created

We initially searched the Cochrane Database of Systematic Reviews using terms including various names of the medicines of interest and “back pain” to find sources for the evidence summary. Where there was no relevant Cochrane review or it was outdated by a more recent, high quality, systematic review (high quality defined as following PRISMA guidelines, and assessing certainty of evidence), we used the non-Cochrane systematic review. If no relevant systematic reviews were available, we referred to single randomised controlled trials for evidence of efficacy.

We also consulted our networks and other experts in the field to identify if any relevant evidence was missing. We did not use observational or non-randomised studies as evidence for efficacy but occasionally referred to them when reporting risk of harm (as these study designs are often more suitable for detecting rare events). When reported certainty of evidence, we report what the systematic review authors report (we did not undertake an independent assessment).

Footnotes

  • Contributors: CMPJ, CWCL, RC, MU, and MS were involved in the conception of the project. SS and JC were invited to join the group after the idea was conceived. CMPJ wrote the first draft. All authors provided critical review and agreed the final version. MS and JC provided a patient perspective. SS provided a perspective from a lower-middle income country.

  • Funding: We thank The Australia & New Zealand Low Back Pain Research Network (ANZBACK) for funding publication costs.

  • Competing interests: We have read and understood the BMJ Group policy on declaration of interests and have no relevant interests to declare.

http://creativecommons.org/licenses/by-nc/4.0/

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References

  1. ↵
    1. Hartvigsen J,
    2. Hancock MJ,
    3. Kongsted A,
    4. et al.,
    5. Lancet Low Back Pain Series Working Group
    . What low back pain is and why we need to pay attention. Lancet2018;391:2356-67. doi:10.1016/S0140-6736(18)30480-X pmid:29573870
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mathieson S,
    2. Valenti L,
    3. Maher CG,
    4. et al
    . Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J2018;27:1136-45. doi:10.1007/s00586-017-5178-4 pmid:28639074
    OpenUrlCrossRefPubMed
  3. ↵
    1. Traeger AC,
    2. Underwood M,
    3. Ivers R,
    4. Buchbinder R
    . Low back pain in people aged 60 years and over. BMJ2022;376:e066928. doi:10.1136/bmj-2021-066928 pmid:35318211
    OpenUrlFREE Full Text
  4. ↵
    1. Jensen RK,
    2. Kongsted A,
    3. Kjaer P,
    4. Koes B
    . Diagnosis and treatment of sciatica. BMJ2019;367:l6273. doi:10.1136/bmj.l6273 pmid:31744805
    OpenUrlFREE Full Text
  5. ↵
    1. Chiarotto A,
    2. Koes BW
    . Nonspecific low back pain. N Engl J Med2022;386:1732-40. doi:10.1056/NEJMcp2032396 pmid:35507483
    OpenUrlCrossRefPubMed
  6. ↵
    1. Schmid AB,
    2. Tampin B,
    3. Baron R,
    4. et al
    . Recommendations for terminology and the identification of neuropathic pain in people with spine-related leg pain. Outcomes from the NeuPSIG working group. Pain2023;164:1693-704. doi:10.1097/j.pain.0000000000002919 pmid:37235637
    OpenUrlCrossRefPubMed
  7. ↵
    1. Henschke N,
    2. Maher CG,
    3. Refshauge KM,
    4. et al
    . Characteristics of patients with acute low back pain presenting to primary care in Australia. Clin J Pain2009;25:5-11. doi:10.1097/AJP.0b013e3181817a8d pmid:19158540
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ferreira GE,
    2. Machado GC,
    3. Abdel Shaheed C,
    4. et al
    . Management of low back pain in Australian emergency departments. BMJ Qual Saf2019;28:826-34. doi:10.1136/bmjqs-2019-009383 pmid:31164487
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. World Health Organization
    . Low back pain. 2023. https://www.who.int/news-room/fact-sheets/detail/low-back-pain.
  10. ↵
    1. Downie AS,
    2. Hancock MJ,
    3. Rzewuska M,
    4. Williams CM,
    5. Lin CC,
    6. Maher CG
    . Trajectories of acute low back pain: a latent class growth analysis. Pain2016;157:225-34. doi:10.1097/j.pain.0000000000000351 pmid:26397929
    OpenUrlCrossRefPubMed
  11. ↵
    1. Chou R,
    2. Shekelle P
    . Will this patient develop persistent disabling low back pain?JAMA2010;303:1295-302. doi:10.1001/jama.2010.344 pmid:20371789
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Hoy D,
    2. Bain C,
    3. Williams G,
    4. et al
    . A systematic review of the global prevalence of low back pain. Arthritis Rheum2012;64:2028-37. doi:10.1002/art.34347 pmid:22231424
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Sharma S,
    2. McAuley JH
    . Low back pain in low- and middle-income countries, part 1: The problem. J Orthop Sports Phys Ther2022;52:233-5. doi:10.2519/jospt.2022.11145 pmid:35536248
    OpenUrlCrossRefPubMed
  14. ↵
    1. Parreira P,
    2. Maher CG,
    3. Steffens D,
    4. Hancock MJ,
    5. Ferreira ML
    . Risk factors for low back pain and sciatica: an umbrella review. Spine J2018;18:1715-21. doi:10.1016/j.spinee.2018.05.018 pmid:29792997
    OpenUrlCrossRefPubMed
  15. ↵
    1. Oliveira CB,
    2. Maher CG,
    3. Pinto RZ,
    4. et al
    . Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J2018;27:2791-803. doi:10.1007/s00586-018-5673-2 pmid:29971708
    OpenUrlCrossRefPubMed
  16. ↵
    World Health Organization. WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings. 2023 https://www.who.int/publications/i/item/9789240081789
  17. ↵
    National Institute for Health and Care Excellence. Self-management - Low back pain and sciatica in over 16s: assessment and management (NICE guideline NG59). 2020. https://www.nice.org.uk/guidance/ng59.
  18. ↵
    1. Qaseem A,
    2. Wilt TJ,
    3. McLean RM,
    4. et al.,
    5. Clinical Guidelines Committee of the American College of Physicians
    . Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Ann Intern Med2017;166:514-30. doi:10.7326/M16-2367 pmid:28192789
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hagen KB,
    2. Hilde G,
    3. Jamtvedt G,
    4. Winnem MF
    . The Cochrane review of bed rest for acute low back pain and sciatica. Spine (Phila Pa 1976)2000;25:2932-9. doi:10.1097/00007632-200011150-00016 pmid:11074682
    OpenUrlCrossRefPubMed
  20. ↵
    1. Pitcher MH,
    2. Von Korff M,
    3. Bushnell MC,
    4. Porter L
    . Prevalence and profile of high-impact chronic pain in the United States. J Pain2019;20:146-60. doi:10.1016/j.jpain.2018.07.006 pmid:30096445
    OpenUrlCrossRefPubMed
  21. ↵
    1. Nahin RL,
    2. Feinberg T,
    3. Kapos FP,
    4. Terman GW
    . Estimated rates of incident and persistent chronic pain among US adults, 2019-2020. JAMA Netw Open2023;6:e2313563. doi:10.1001/jamanetworkopen.2023.13563 pmid:37191961
    OpenUrlCrossRefPubMed
  22. National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s: assessment and management (NICE guideline NG59). 2020. https://www.nice.org.uk/guidance/ng59
  23. ↵
    1. Gomes LA,
    2. Cruz EB,
    3. Henriques AR,
    4. Branco JC,
    5. Canhão H,
    6. Rodrigues AM
    . Patients’ self-reported medical care for low back pain: a nationwide population-based study. BMJ Open2022;12:e060966. doi:10.1136/bmjopen-2022-060966 pmid:36691148
    OpenUrlCrossRefPubMed
  24. ↵
    1. Goertz CM,
    2. Long CR,
    3. English C,
    4. Meeker WC,
    5. Marchiori DM
    . Patient-reported physician treatment recommendations and compliance among U.S. adults with low back pain. J Altern Complement Med2021;27(S1):S99-105. doi:10.1089/acm.2020.0392 pmid:33788609
    OpenUrlCrossRefPubMed
  25. ↵
    1. Di Gangi S,
    2. Pichierri G,
    3. Zechmann S,
    4. Rosemann T,
    5. Plate A
    . Prescribing patterns of pain medications in unspecific low back pain in primary care: A retrospective analysis. J Clin Med2021;10:1366. doi:10.3390/jcm10071366 pmid:33810469
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ekor M
    . The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol2014;4:177. doi:10.3389/fphar.2013.00177 pmid:24454289
    OpenUrlCrossRefPubMed
  27. ↵
    1. Asrar MM,
    2. Ghai B,
    3. Pushpendra D,
    4. Bansal D
    . Psychosocial morbidity profile in a community based sample of low back pain patients. Sci Rep2021;11:2610. doi:10.1038/s41598-021-82324-y pmid:33510413
    OpenUrlCrossRefPubMed
  28. ↵
    1. Bova G,
    2. Domenichiello A,
    3. Letzen JE,
    4. et al
    . Developing consensus on core outcome sets of domains for acute, the transition from acute to chronic, recurrent/episodic, and chronic pain: results of the INTEGRATE-pain Delphi process. EClinicalMedicine2023;66:102340. doi:10.1016/j.eclinm.2023.102340 pmid:38089861
    OpenUrlCrossRefPubMed
  29. ↵
    1. Machado GC,
    2. Maher CG,
    3. Ferreira PH,
    4. et al
    . Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ2015;350:h1225. doi:10.1136/bmj.h1225 pmid:25828856
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Machado GC,
    2. Maher CG,
    3. Ferreira PH,
    4. Day RO,
    5. Pinheiro MB,
    6. Ferreira ML
    . Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Ann Rheum Dis2017;76:1269-78. doi:10.1136/annrheumdis-2016-210597 pmid:28153830
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Enthoven WTM,
    2. Roelofs PDDM,
    3. Deyo RA,
    4. van Tulder MW,
    5. Koes BW
    . Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev2016;2:CD012087. doi:10.1002/14651858.CD012087 pmid:26863524
    OpenUrlCrossRefPubMed
  32. ↵
    1. Ferreira GE,
    2. McLachlan AJ,
    3. Lin CC,
    4. et al
    . Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ2021;372:m4825. doi:10.1136/bmj.m4825 pmid:33472813
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Abdel Shaheed C,
    2. Maher CG,
    3. Williams KA,
    4. Day R,
    5. McLachlan AJ
    . Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med2016;176:958-68. doi:10.1001/jamainternmed.2016.1251 pmid:27213267
    OpenUrlCrossRefPubMed
  34. ↵
    1. Enke O,
    2. New HA,
    3. New CH,
    4. et al
    . Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ2018;190:E786-93. doi:10.1503/cmaj.171333 pmid:29970367
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. van Tulder MW,
    2. Touray T,
    3. Furlan AD,
    4. Solway S,
    5. Bouter LM
    . Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev2003;2003:CD004252. doi:10.1002/14651858.CD004252 pmid:12804507
    OpenUrlCrossRefPubMed
  36. ↵
    1. Cashin AG,
    2. Folly T,
    3. Bagg MK,
    4. et al
    . Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ2021;374:n1446. doi:10.1136/bmj.n1446 pmid:34233900
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Chou R,
    2. Pinto RZ,
    3. Fu R,
    4. et al
    . Systemic corticosteroids for radicular and non-radicular low back pain. Cochrane Database Syst Rev2022;10:CD012450.pmid:36269125
    OpenUrlPubMed
  38. ↵
    Chou R, Wagner J, Ahmed AY, et al. Living systematic review on cannabis and other plant-based treatments for chronic pain: 2022 update. Agency for Healthcare Research and Quality (US), 2022. https://www.ncbi.nlm.nih.gov/books/NBK586045/
  39. ↵
    1. Derry S,
    2. Wiffen PJ,
    3. Kalso EA,
    4. et al
    . Topical analgesics for acute and chronic pain in adults ‐ an overview of Cochrane Reviews. Cochrane Database Syst Rev2017; doi:10.1002/14651858.CD008609.pub2 .
    OpenUrlCrossRef
    1. Mathie RT,
    2. Ramparsad N,
    3. Legg LA,
    4. et al
    . Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis. Syst Rev2017;6:63. doi:10.1186/s13643-017-0445-3 pmid:28340607
    OpenUrlCrossRefPubMed
  41. ↵
    1. Oltean H,
    2. Robbins C,
    3. van Tulder MW,
    4. Berman BM,
    5. Bombardier C,
    6. Gagnier JJ
    . Herbal medicine for low-back pain. Cochrane Database Syst Rev2014;2014:CD004504. doi:10.1002/14651858.CD004504.pub4 pmid:25536022
    OpenUrlCrossRefPubMed
  42. ↵
    1. Kaptchuk TJ,
    2. Hemond CC,
    3. Miller FG
    . Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ2020;370:m1668. doi:10.1136/bmj.m1668 pmid:32690477
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Hultcrantz M,
    2. Rind D,
    3. Akl EA,
    4. et al
    . The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol2017;87:4-13. doi:10.1016/j.jclinepi.2017.05.006 pmid:28529184
    OpenUrlCrossRefPubMed
  44. ↵
    1. Roberts E,
    2. Delgado Nunes V,
    3. Buckner S,
    4. et al
    . Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis2016;75:552-9. doi:10.1136/annrheumdis-2014-206914 pmid:25732175
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Rahme E,
    2. Pettitt D,
    3. LeLorier J
    . Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum2002;46:3046-54. doi:10.1002/art.10604 pmid:12428249
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Rahme E,
    2. Barkun A,
    3. Nedjar H,
    4. Gaugris S,
    5. Watson D
    . Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol2008;103:872-82. doi:10.1111/j.1572-0241.2008.01811.x pmid:18371130
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Machado GC,
    2. Abdel-Shaheed C,
    3. Underwood M,
    4. Day RO
    . Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain. BMJ2021;372:n104. doi:10.1136/bmj.n104 pmid:33514562
    OpenUrlFREE Full Text
  48. ↵
    1. Ferguson JM
    . SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry2001;3:22-7.pmid:15014625
    OpenUrlCrossRefPubMed
  49. ↵
    1. Jones CMP,
    2. Day RO,
    3. Koes BW,
    4. et al.,
    5. OPAL Investigators Coordinators
    . Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet2023;402:304-12. doi:10.1016/S0140-6736(23)00404-X pmid:37392748
    OpenUrlCrossRefPubMed
  50. ↵
    1. Baldini A,
    2. Von Korff M,
    3. Lin EHB
    . A review of potential adverse effects of long-term opioid therapy: A practitioner’s guide. Prim Care Companion CNS Disord2012;14:PCC.11m01326. doi:10.4088/PCC.11m01326 pmid:23106029
    OpenUrlCrossRefPubMed
  51. ↵
    1. Mathieson S,
    2. Maher CG,
    3. McLachlan AJ,
    4. et al
    . Trial of pregabalin for acute and chronic sciatica. N Engl J Med2017;376:1111-20. doi:10.1056/NEJMoa1614292 pmid:28328324
    OpenUrlCrossRefPubMed
  52. ↵
    1. Reddy S,
    2. Patt RB
    . The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage1994;9:510-4. doi:10.1016/0885-3924(94)90112-0 pmid:7531735
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Friedman BW,
    2. Irizarry E,
    3. Solorzano C,
    4. et al
    . Diazepam is no better than placebo when added to naproxen for acute low back pain. Ann Emerg Med2017;70:169-176.e1. doi:10.1016/j.annemergmed.2016.10.002 pmid:28187918
    OpenUrlCrossRefPubMed
  54. ↵
    1. Edinoff AN,
    2. Nix CA,
    3. Hollier J,
    4. et al
    . Benzodiazepines: Uses, dangers, and clinical considerations. Neurol Int2021;13:594-607. doi:10.3390/neurolint13040059 pmid:34842811
    OpenUrlCrossRefPubMed
  55. ↵
    1. Bebee B,
    2. Taylor DM,
    3. Bourke E,
    4. et al
    . The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust2021;214:370-5. doi:10.5694/mja2.51014 pmid:33846971
    OpenUrlCrossRefPubMed
  56. ↵
    1. Mathieson S,
    2. Kasch R,
    3. Maher CG,
    4. et al
    . Combination drug therapy for the management of low back pain and sciatica: systematic review and meta-analysis. J Pain2019;20:1-15. . doi:10.1016/j.jpain.2018.06.005 pmid:30585164
    OpenUrlCrossRefPubMed
  57. ↵
    NHS Specialist Pharmacy Service. Clinical evidence for homeopathy. 2017. https://www.england.nhs.uk/wp-content/uploads/2017/11/sps-homeopathy.pdf.
  58. ↵
    1. Langford AV,
    2. Lin CCW,
    3. Bero L,
    4. et al
    . Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust2023;219:80-9. doi:10.5694/mja2.52002 pmid:37356051
    OpenUrlCrossRefPubMed
  59. ↵
    1. Boon M,
    2. van Dorp E,
    3. Broens S,
    4. Overdyk F
    . Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events. Ann Palliat Med2020;9:542-57. doi:10.21037/apm.2019.12.09 pmid:32036672
    OpenUrlCrossRefPubMed
Back to top